For several decades, it has been known that oestrogens are essential for human health. The discovery that there are two oestrogen receptors (ERs), ER␣ and ER␤, has facilitated our understanding of how the hormone exerts its physiological effects. The ERs belong to the family of ligand-activated nuclear receptors, which act by modulating the expression of target genes. Studies of ER-knockout (ERKO) mice have been instrumental in defining the relevance of a given receptor subtype in a certain tissue. Phenotypes displayed by ERKO mice suggest diseases in which dysfunctional ERs might be involved in aetiology and pathology. Association between single-nucleotide polymorphisms (SNPs) in ER genes and disease have been demonstrated in several cases. Selective ER modulators (SERMs), which are selective with regard to their effects in a certain cell type, already exist. Since oestrogen has effects in many tissues, the goal with a SERM is to provide beneficial effects in one target tissue while avoiding side effects in others. Refined SERMs will, in the future, provide improved therapeutic strategies for existing and novel indications. 
The oestrogen receptors (ERs)
For several decades, it has been known that the steroid hormone oestrogen is involved in disease. As early as 1896, Dr George Beatson conducted experiments in which removal of the ovaries from post-menopausal women with advanced breast cancer, led to shrinkage of the tumour and improved prognosis (reviewed in [1] ). In 1916, ovariectomy of mice with a propensity to develop mammary carcinoma was found to reduce the incidence of tumours. In 1923, it was discovered that oestrogenic hormones are produced by the ovaries. In the late 1950s, the existence of a receptor molecule that could bind 17␤-oestradiol was discovered by Jensen and Jacobson (reviewed in [1] ); in 1986, the first ER was cloned [2, 3] . This receptor was regarded as the only existing ER for 10 years, until members of our laboratory discovered a second ER [4] . The two receptors are today known as ER␣ and ER␤ respectively, and belong to the family of ligand-activated nuclear receptors. These receptors exert their effects by modulating the expression of target genes. ER␣ and ER␤ show a high degree of similarity when compared at the amino-acid level ( Figure 1) ; however, it is clear that the receptors display differences with regard to ligand-binding and transcriptional activation. The receptors can be detected in a broad spectrum of tissues. In some organs, both receptor subtypes are expressed at similar levels, whereas in others, one or the other subtype predominates. ER␣ is, for example, the major receptor in the liver, while ER␤ is the main receptor in the intestines. Both receptors can be found in heart and bone. Also, both receptor subtypes may be present in the same tissue, but in different cell types. For instance, ER␣ is found in the stromal cells and ER␤ in the epithelial cells of the prostate. Mice lacking one or both of the receptor subtypes have been, and still are, instrumental in increasing our understanding of the role of oestrogen and its receptors in physiology and disease [5] . The ER-knockout (ERKO) mice display varying phenotypes in bone, brain, mammary gland, immune system, cardiovascular system and prostate, all of which will be discussed further in this review. Both male and female ␣ERKO and ␣␤ERKO mice are completely infertile, whereas ␤ERKO males exhibit normal fertility [5] ; ␤ERKO females show decreased fertility [6] . The infertility in the ERKO models can be partly accounted for by an inability to ovulate; in fact, both ERs are required for ovulation to occur efficiently.
ER modulators in physiology and disease
ER modulators, agonists and antagonists, have a widespread use in clinical practice today. The total world market for this class of drugs is worth billions of dollars. The introduction of ER antagonists for the treatment of hormonedependent breast cancer represents a milestone in the treatment of this lifethreatening disease. ER agonists are often used to alleviate the symptoms associated with post-menopausal syndrome. However, the risk-benefit profile of this substitution therapy needs to be considered.
The following sections focus on some selected diseases in which oestrogen and its receptors have been implicated.
ERs and breast cancer
It is generally believed that breast tumours, at least initially, are dependent on the stimulatory effects of oestrogens, directly or indirectly, and it is thought that oestrogens act by inducing the expression of paracrine growth factors and their receptors. However, many breast tumours eventually progress to an oestrogen-independent growth phenotype. Tamoxifen and similar antioestrogens are currently the first-line therapy for treatment of hormonedependent breast cancer [1] .
Various ER transcripts have been found in breast carcinomas [7, 8] and protein products corresponding to variant ERs have been described [9] . Splicing of ER␣ precursor RNA frequently leads to variants, lacking one or more exons, that have been associated with breast cancer progression. The most frequent splice variants are exon 4 or exon 7 deletions [10] . Exon 4 comprises the hinge region and the very N-terminal part of the ligand-binding domain (LBD), and exon 7 contains part of the LBD. Of these two, only the exon 7 deletion has so far been detected at the protein level [9] . Single exon deletions in ER␣ can be found in a majority of normal breast tissues, while an increased frequency of multiple exon deletions is found in tumours [9] . Normal and cancerous tissues display a variety of distinct profiles regarding ER␣ wild-type (WT), ER␤ WT, and ER␣ and ER␤ splice variants at both mRNA and protein levels. This heterogeneity in ER isoform profiles is suggested to result in variations in oestrogen signalling, and might affect breast cancer risk, hormone-responsiveness and survival [9] . Some data suggest that the ER␤1 (ER␤ WT) transcript is down-regulated in breast tumorigenesis [11] [12] [13] , but this was not shown to be consistent for all tumour grades [14] . A higher level of ER␤2 (ER␤ CX), compared with the ER␤1 transcript, was reported in human breast cancer cell lines, as well as in breast tumours and normal breast tissue [12] [13] [14] [15] . ER␤ CX is a variant of ER␤ WT in which the last exon (LIV; see Figure 2B ) is spliced away and replaced with the CX exon. We have shown that methylation of the ER␤ promoter is inversely correlated with ER␤ expression in breast cancer tumours and cell lines [15] . Since promoter methylation is frequently observed in cancer, these data suggest that ER␤ is a possible tumour-suppressor gene.
ER␤ is found in ductal, lobular epithelial and stromal cells of the rodent mammary gland (reviewed in [16] ). ER␣, on the other hand, is only found in the ductal and lobular epithelial cells, and not in the stroma. The ␣ERKO mice display severe retardation of mammary gland development and show rudimentary glands at adulthood [16] . Studies of the ␤ERKO mice indicate that ER␤ is not necessary for ductal growth of the gland, but seems to be important for the organization and adhesion of epithelial cells [16] .
ERs and prostate cancer
Prostate cancer is the most frequently diagnosed malignancy and the second most common cause of death among men in the U.S.A. Prostate cancer is age-dependent and the incidence increases after the age of 40. The growth and development of the prostate is under endocrine control and both androgens and oestrogens play important roles [17] . Androgens are essential for stimulating normal development, growth and secretory activities of the prostate, whereas oestrogens are generally regarded as inhibitors of growth. Combined androgen and oestrogen treatment has been shown to induce prostatic dysplasia and adenocarcinoma [18] . These results demonstrate that malignant changes in the prostate gland may be dependent upon both androgenic and oestrogenic effects. Oestrogens have been shown to induce growth of LNCaP prostate cancer cells, which can be inhibited by antioestrogens [19] . However, this cell line contains a mutant androgen receptor (AR), which results in promiscuity in hormone binding and receptor activation, making interpretation of these results difficult. In an androgendecreased environment, oestrogen, through ER␣, causes benign prostate hyperplasia, dysplasia and cancer [20] . Studies have shown that antioestrogens and specific ER modulators (SERMs) can delay and suppress prostate carcinogenesis [20] . Both ER subtypes are found in the ventral prostate, but are located in different cell types [16] . ER␣ is found in the stromal cells and ER␤ in the epithelial cells, in which ER␣ is absent. The oestrogenic effects in the prostate may therefore be exerted by both ERs, but in different cells. Studies of transgenic mice show interesting phenotypes with hyperplastic prostates in both ␤ERKO and aromataseknockout (ARKO) mice, but not in ␣ERKO mice [16] . In prostates from ␤ERKO mice, most epithelial cells express the proliferation antigen Ki-67, and the tissue contains several hyperplastic foci [16] . In contrast, the prostate epithelium of their WT littermates show no hyperplasia and with only a few cells expressing Ki-67 [16] . The hyperplasia is thought to be directly caused by lack of ER␤ and its anti-proliferative function in the prostate. The hyperplasia in ARKO mice may also be due to increased androgen and prolactin levels, secondary effects caused by the general loss of aromatase, the enzyme that converts androgens into oestrogens [16] .
ERs and cardiovascular disease
Women present a higher risk for cardiovascular disease (CVD) after the onset of menopause, a phenomenon thought to be due to the loss of endogenous oestrogen. Accordingly, in some studies, reduced cardiovascular risks have been observed in subjects undergoing hormonal replacement therapy (HRT). Oestrogens, acting via ERs in the cardiovascular system [21] , are thought to be important in prevention of CVD in women. Oestrogens have favourable effects on lipid profile, tone of vascular smooth muscle cells and fibrinogen levels [22] . When prescribed alone, however, oestrogen increases the risk of endometrial cancer and is therefore taken in combination with progestins, which are anti-proliferative in the uterus. Importantly, however, an oestrogen-progestin arm of the first prospective study of oestrogen and oestrogen-progestin for prevention of CVD was terminated early owing to an unacceptable risk profile. The Women's Health Initiative (WHI) reported that oestrogen in combination with progestin does not confer cardiac protection and may even increase the risk of CVD among healthy post-menopausal women, especially during the first year of treatment [23] . Furthermore, there was an increased risk of ischaemic stroke in generally healthy post-menopausal women [24] . However, the oestrogen-alone arm of the study is on-going. Results from the study of ERKO mice suggest that ER␣ is important in the pathophysiology of the vessel wall [25] . The ␤ERKO mice display a phenotype with abnormalities in ion-channel function and an age-related sustained systolic and diastolic hypertension [25] .
ERs and osteoporosis
Oestrogen and its receptors are known to be important in the regulation of bone metabolism. Oestrogen deficiency beginning at the menopause is a major pathogenic factor in the development of osteoporosis in post-menopausal women. The ERs are expressed in most cell types in bone [26] . A male patient with a non-functional ER␣ gene showed abnormal post-pubertal bone elongation [27] . Mice lacking the ER␣ gene show minor skeletal abnormalities with reduced longitudinal bone growth and small reductions in bone mineral density (BMD) [26] . Studies of female ␤ERKO mice, which lack ER␤, indicate that ER␤ is responsible for the repression of the growth-promoting effect of oestrogen on bone mediated via ER␣ [26] .
ERs and diseases of the central nervous system (CNS)
ERs have also been implicated in various disorders of the brain. The receptors are expressed in the CNS, where they are thought to play important roles [16] . The distribution pattern suggests different functions for the two receptors. ␤ERKO mice show an interesting phenotype with severe neuronal deficiency in the cortex, revealing an important role for ER␤ in neuronal migration [16, 28] . ␣ERKO mice show no morphological abnormalities in the brain. Oestrogen has been proposed to act as a neuroprotectant. Deprivation of oestrogen as a result of the menopause is associated with an increased risk of Alzheimer's disease and Parkinson's disease [29] . Oestrogen replacement therapy may reduce this risk in both men and women.
ERs and diseases of the immune system
Oestrogen and its receptors also play important roles in the immune system. Ovariectomized mice show splenomegaly [30] and an increased production of haematopoietic cells [31] . Proliferation of pluripotent bone marrow stem cells is negatively regulated by oestrogen [31] . ␤ERKO mice develop pronounced splenomegaly by 1.5 years of age [31] , a phenomenon that is much more severe in females than in males. Interestingly, the absence of ER␤ results in a myeloproliferative disease resembling human chronic myeloid leukaemia with lymphoid blast crisis. These intriguing results suggest a role for ER␤ in regulating the pluripotent haematopoietic progenitor cells and make the ␤ERKO mice a potential model for lymphoid and myeloid leukaemia [31] .
ER polymorphisms and mutations in relation to disease
A few studies have been published in which the ER␣ and ER␤ genes have been screened to identify mutations which change the amino acid sequence of the proteins, and are therefore candidates to change receptor function. Various ER␣ variants, including deletion variants, have been found in breast carcinomas [9] . A point mutation in the ER␣ gene that generates a stop codon, resulting in a truncated ER␣ protein, has been reported in one male patient [27] . This patient is suffering from osteoporosis and infertility. In a systematic mutation screening of ER␤ in probands of different mass extremes, five different genetic variants were identified [32] . Our laboratory has screened approx. 50 patients diagnosed with various infertility syndromes such as polycystic ovary syndrome, premature ovarian failure and endometriosis, for mutations in the ER␤ exons, only to reveal a few new variations, none of which cause a change in the primary structure of the protein (M. Nilsson and M. Zelada-Hedman unpublished work). We have also screened 34 primary breast cancer specimens without detecting any novel variants (M. Nilsson, unpublished work).
Single-nucleotide polymorphisms (SNPs) are base-pair changes that exist naturally in a population. Usually, variants that occur at an allele frequency exceeding 1% are referred to as SNPs. SNPs provide important tools for human genetic studies. A set of polymorphisms are scored in cases and controls. If an association is detected, i.e. a specific nucleotide is more common at one position in the gene in cases compared with controls, this indicates that the polymorphism itself, or some other change in the same or neighbouring genes, is related to the disease. A number of polymorphisms have been reported in the ERs. An overview of commonly scored ER␣ and ER␤ variants is given in Figure 2 . Generally, these SNPs do not change the amino acid sequence of the resulting ER proteins and thus are not likely to change receptor function. However, that they change the expression level of the receptor proteins cannot be excluded. A number of case-control studies have investigated a possible association between ER␣ or ER␤ SNPs and disease. Studies of coronary artery disease (CAD) patients failed to show an association with the ER␣ variants B and C (see Figure 2A ) [33] . Conflicting results have been reported for association between the ER␣ variants E and F ( Figure 2A ) and BMD [34] , probably because of differences in screened populations. Another study reported that ER␣ variant B (Figure 2A ) might be a risk factor for prostate cancer [35] . We have shown an association between ER␤ SNPs I and J ( Figure 2B ) and bulimic patients [36] , and others have shown an association between ER␤ D and anorexia nervosa [37] . Interestingly, ER␤ is located on chromosome 14, in a recently identified region that meets the criteria for genome-wide suggestive linkage with bulimia nervosa [38] . However, a German study did not provide evidence for an association between bulimia nervosa and ER␤ polymorphisms D and I [32] . Other studies have investigated the possible association between a dinucleotide repeat polymorphism (E in Figure 2B ) located in the flanking region of the human ER␤ gene and various clinical parameters. A possible association between this polymorphism and hypertension in Japanese women was reported in [39] . The dinucleotide repeat was also suggested to be associated with BMD [40] and androgen levels in women [41] , but not with autoimmune thyroid diseases in another study [42] . Association studies of the same ER␤ gene polymorphism found a correlation with higher BMD in pre-menopausal, but not post-menopausal Chinese women [43] , suggesting that the ER␤ gene may have a modulatory role in bone metabolism in young adulthood. Six different polymorphisms in ER␤ (B, C, D, E, H and I) were studied in a sporadic breast cancer material; however, no differences were found in the allelic distribution of the six studied polymorphisms between the breast cancer and control groups [44] .
Conclusion
The ERs are known to have important roles in many different diseases, including osteoporosis, prostate cancer, breast cancer, cardiovascular disease and diseases of the CNS. Recently, other interesting functions of the ERs have been proposed. Studies of mice revealed that absence of ER␤ results in a myeloproliferative disease resembling human chronic myeloid leukaemia with lymphoid blast crisis. This might indicate a role for ER␤ in regulating the differentiation of pluripotent haematopoietic progenitor cells. Future association studies on large populations will contribute to our understanding of the role of ER␣ and ER␤ for the development of disease in humans. We are expecting an explosion in our understanding of the molecular effects of oestrogen in target tissues in relation to physiology and disease. This will be possible using modern gene expression profiling and proteomics technologies. Furthermore, receptor-selective ligands, which are currently being developed, will provide important tools to understand ER biology and studies in ER␣-and/or ER␤-deficient mice will clarify the importance of a specific receptor for a given effect. These studies will aid the development of SERMs with well-characterized and optimal effects in oestrogen-responsive tissues. SERMs are already available; however, existing SERMs are modest in their desired tissue-selective activity and have undesired side effects. Therefore a great need exists for novel SERMs with a more refined therapeutic profile with optimal selectivity and activity in oestrogen-responsive tissues. 
Summary

